Etude de phase 3, évaluation de l’ajout du darolutamide à l’hormonothérapie et à la radiothérapie chez des patients atteints d’un cancer de prostate avec métastases ganglionnaires pelviennes

Essai clinique

Type : Académique
Statut : Ouvert
Phase : III
Étape du traitement : Traitements combinés
Date d'ouverture : 01/04/2022
Date clôture : 28/02/2027
Promoteur : Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Progression du cancer: À distance
Résumé :

Prospective, multicenter, comparative, randomized placebo-controlled Phase III trial - patients with hormone-naïve prostate cancer and pelvic lymph nodes metastases

Domaines/spécialités :
  • Cancers uro-génitaux
    • Prostate
Pathologies :
  • Tumeur maligne de la prostate - Cim10 : C61
Liens externes :

Critères de population

Sexe : Homme
Age minimum : 18 ans
Age maximum : 120 ans
Critères d’inclusion :
  1. Newly diagnosed, histologically confirmed prostate adenocarcinoma
  2. ≥ 18 years old.
  3. Initial staging with Pelvic MRI, CT-scan and or Choline or PSMA PET-CT
  4. Any T stage
  5. Pelvis lymph nodes metastases (upper limit defined as the L4/L5 interspace).
  6. Intention to treat with long-term androgen deprivation therapy (24 months).
  7. Hormonal therapy with LH-RH agonist or antagonist is allowed up to 2-months prior to randomization.
  8. Able to receive either protocol therapy and life expectancy of at least 36 months, ECOG Performance Status (PS) 0-2.
  9. Blood counts at screening: hemoglobin ≥ 9.0 g/dl, absolute neutrophil count ≥ 1500/μl (1.5x109/l), platelet count ≥ 100,000/μl (100x109/l ) (patient must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).
  10. Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) < 2.5 x upper limit of normal (ULN), total bilirubin < 1.5 x ULN (except patients with a diagnosis of Gilbert's disease), creatinine < 2.0 x ULN.
  11. Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method during the study treatment and for 3 months after the end of the study treatment.
  12. Written informed consent.
  13. Willing and expected to comply with follow-up schedule.
  14. Affiliated to the social security system.
Critères d’exclusion :
  1. Lymph nodes metastases outside of the pelvis
  2. Bone or visceral metastases
  3. Prior systemic therapy for locally-advanced prostate cancer.

  4. Prior treatment with:

    • Second generation AR inhibitors such as enzalutamide, ARN-509, ODM-201, other investigational AR inhibitors,
    • CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or
    • Oral ketoconazole longer than for 28 days.
    • Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride) or AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 28 days before randomization.
  5. Prior chemotherapy or immunotherapy for prostate cancer, except adjuvant/neoadjuvant treatment, completed > 2 years before randomization.
  6. Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomization.
  7. Severe or uncontrolled concurrent disease, infection or co-morbidity that, in the opinion of the investigator, would make the patient inappropriate for enrolment.
  8. Initiation of treatment with bisphosphonate or denosumab within 12 weeks before randomization. Patients receiving bone loss prevention treatment on a stable dose of e.g. bisphosphonate or denosumab for at least 28 days before randomization can continue the treatment during the study.
  9. Known hypersensitivity to the study treatment (RT, ADT, darolutamide/placebo) or any of its ingredients.
  10. Major surgery within 28 days before randomization.
  11. Any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV or arterial thromboembolic event.
  12. Uncontrolled hypertension as indicated by a resting systolic BP > 160 mmHg or diastolic BP > 100 mmHg at screening. Patients may be re-screened after adjustments of anti- hypertensive medications.
  13. Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which chemotherapy has been completed > 5 years ago and from which the patient has been disease-free.
  14. Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
  15. Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
  16. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug within 28 days before randomization.
  17. Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures.
  18. Unable to swallow study medications and comply with study requirements.
  19. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
  20. History of bilateral hip replacements making IMRT impossible
  21. Contra-indications for the administration of any of the study treatments (RT, ADT, Darolutamide/placebo) or any of its ingredients.
  22. Patient under guardianship, administrative tutorship and incapable to give informed consent

Centre d'investigation

En cours
Nom : Centre Georges François Leclerc - CGFL
Ville : DIJON (21)
RESPONSABLE MÉDICAL
Nom : Dr MARTIN
Prénom : Etienne
Téléphone : Non disponible
Email : emartin@cgfl.fr
CONTACT TECHNIQUE
Nom : BATAILLARD
Prénom : Philippe
Téléphone : 03 45 34 81 37
Email : pbataillard@cgfl.fr

Référentiels Oncologik

Aucun référentiel n'est lié à cet essai.